Dako A/S (Acquired by Agilent Technologies, Inc.) And U.S.-Based Merck & Co., Inc. To Collaborate On Companion Diagnostic Test For Analysis Of Tumor PD-L1 Levels

GLOSTRUP, Denmark, May 30, 2014 (GLOBE NEWSWIRE) -- Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics , today announced a collaboration with Merck & Co., Inc. ( known as MSD outside the United States and Canada, through an affiliate) to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the treatment of cancer.

Help employers find you! Check out all the jobs and post your resume.